Fragment-based hit identification: thinking in 3D.
Drug Discov Today
; 18(23-24): 1221-7, 2013 Dec.
Article
em En
| MEDLINE
| ID: mdl-23906694
ABSTRACT
The identification of high-quality hits during the early phases of drug discovery is essential if projects are to have a realistic chance of progressing into clinical development and delivering marketed drugs. As the pharmaceutical industry goes through unprecedented change, there are increasing opportunities to collaborate via pre-competitive networks to marshal multifunctional resources and knowledge to drive impactful, innovative science. The 3D Fragment Consortium is developing fragment-screening libraries with enhanced 3D characteristics and evaluating their effect on the quality of fragment-based hit identification (FBHI) projects.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Desenho de Fármacos
/
Bibliotecas de Moléculas Pequenas
/
Descoberta de Drogas
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article